Innovations at the intersection of advancements in technology and biology will drive major improvements in the quality of our health and the cost of healthcare. At Menlo, we invest at that intersection—backing breakthrough digital health companies (vertical SaaS and digital care) and novel life sciences companies (therapeutic platforms and transformative technologies).
The 5 Ps of Therapeutics Investing at Menlo
At Menlo, we believe the pace of innovation in new medicines will continue to accelerate, powered by the combination of advances in biology, advances in information technology, and even the lasting implications of the global pandemic.
The pandemic’s pressures compressed trends toward digital and virtual care that might otherwise have taken years into a few months. But which of these trends will endure, or even continue to accelerate, even once the pandemic has been brought under control?
Announcing the Digital Health Founder’s Fellowship
We started the Digital Health Founder’s Fellowship to help the next generation of digital health founders and startups build sustainable businesses that can realize the unfulfilled promise of technology-enabled healthcare.
Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.
Riva Health founders Tuhin Sinha and Dag Kittlaus discuss their critical mission to revolutionize cardiovascular healthcare; their long histories with Menlo partners Greg Yap and Shawn Carolan; how they were introduced to each other; and the whirlwind journey to FDA approval.